Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antivirals against HIV-1.

Ian Frank1

  • 1Infectious Diseases Division, 502 Johnson Pavilion, University of Pennsylvania, Philadelphia, PA 19104-6073, USA. franki@mail.med.upenn.edu

Clinics in Laboratory Medicine
|September 25, 2002
PubMed
Summary

The development of HIV viral load assays in 1996 revolutionized treatment. This advancement, alongside protease inhibitors, significantly reduced AIDS-related deaths and illness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein.

Vaccine·2026
Same author

Distinct Antibody Fc-profiles in Lymph During Homeostasis and Chronic HIV Infection.

Pathogens & immunity·2026
Same author

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083.

The Journal of infectious diseases·2025
Same author

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.

Science translational medicine·2025
Same author

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302).

Annals of internal medicine·2025
Same author

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.

Emerging microbes & infections·2025

Area of Science:

  • Infectious Diseases
  • Virology
  • Public Health

Background:

  • HIV/AIDS emerged as a major global health crisis in the 1980s.
  • By 1994, AIDS was the leading cause of death in the US for ages 15-45.
  • Early antiretroviral therapy (ART) began in 1987 with zidovudine.

Purpose of the Study:

  • To highlight the impact of diagnostic advancements on HIV/AIDS treatment.
  • To underscore the significance of viral load monitoring in evaluating ART efficacy.
  • To explain the role of protease inhibitors in improving patient outcomes.

Main Methods:

  • Review of historical data on HIV/AIDS morbidity and mortality.
  • Analysis of the timeline of key therapeutic and diagnostic developments.
  • Examination of the impact of specific drug classes (NRTIs, protease inhibitors) and assays.

Main Results:

  • The introduction of HIV viral load assays in 1996 enabled precise measurement of viral RNA in plasma.
  • This technological breakthrough allowed for effective evaluation of antiviral therapy efficacy.
  • The combination of viral load monitoring and protease inhibitors led to a significant decrease in HIV/AIDS-related morbidity and mortality.

Conclusions:

  • The development of HIV viral load assays was a critical turning point in managing HIV/AIDS.
  • Effective monitoring and combination therapy dramatically improved prognosis and reduced disease burden.
  • Advances in diagnostics and therapeutics transformed HIV/AIDS from a rapidly fatal disease to a manageable chronic condition.

Related Experiment Videos